In this issue: Statins and liver function; dosing timing for thyroxine; rivaroxaban for VTE, DVT, and stroke; echinacea and the common cold; and FDA actions.
This paper presents two parallel studies that evaluate the safety and efficacy of oral rivaroxaban in the treatment of acute deep venous thrombosis (DVT) and in continuing prophylaxis for recurrence.
The pendulum has been swinging away from doing early deliveries without indications, but the question remains: What is early?
Conducted in a 700+ bed tertiary care, urban academic teaching hospital with a trauma center and referral center for high-risk obstetrics, this retrospective cohort study involved the procedures of 86 surgeons and 134 OB/GYNs between 1999 and 2008.
The Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure is currently updating its work in JNC-7 in an effort to help physicians provide safe, effective, and patient-centered care for those with elevated blood pressure.
New information from two case control studies of the transdermal contraceptive (Ortho Evra, Ortho-McNeil Pharmaceutical, Raritan, NJ) indicates no increased risk of heart attack or stroke for women who choose the patch, but data conflict on the occurrence of venous thromboembolism (VTE).
